Details of the Drug

General Information of Drug (ID: DMI0RHA)

• Drug Name: Inebilizumab

Indication

Disease Entry	ICD 11	Status	REF
Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[1]

• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2980 mgday/L [2]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 108 mg/L [2]
  Clearance: The sytemic clearance of drug is 0.19 L/day [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 18 days [2]
  Metabolism: The drug is metabolized via the degraded through proteolysis [2]
  Vd: The volume of distribution (Vd) of drug is 2.95 L [2]
• Cross-matching ID:
  DrugBank ID: DB12530
  TTD ID: D0XH3V

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Inhibitor	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Neuromyelitis optica spectrum disorder
• ICD Disease Classification: 8E4A.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Inebilizumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Inebilizumab and Ozanimod.	Multiple sclerosis [8A40]	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] FDA Approved Drug Products: Uplizna (inebilizumab-cdon) injection
• [3] Cerner Multum, Inc. "UK Summary of Product Characteristics.".